Emmaus Life Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

CONVERTIBLE DEBT AND EQUITY FINANCINGS (Details Textual)

CONVERTIBLE DEBT AND EQUITY FINANCINGS (Details Textual) (September 2014 Notes [Member], USD $)	12 Months Ended
	Sep. 30, 2014
September 2014 Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	5.00%
Debt Instrument, Convertible, Conversion Price	$ 0.25
Debt Instrument, Face Amount	$ 2,500,000
Debt Instrument, Term	18 months
Debt Instrument, Convertible, Terms of Conversion Feature	(i) automatically upon the closing of a qualified offering of no less than $5 million at a conversion price equal to the lesser of $0.25 or 70% of the lowest cost of Common Stock offered by the Company, but in no event less than $0.10 per share or (ii) voluntarily within 15 days of maturity at the lesser of a conversion price equal to $0.25 or the lowest cost of Common Stock offered by the Company, but in no event less than $0.10 per share.

- Definition

Description of the conversion terms of a debt instrument which may include the conversion ratio (including all potential conversion ratios if contingently adjustable), type of debt or equity security into which the debt is convertible, the dollars of debt or the number of shares into which the instrument is convertible (or potentially convertible into), the conversion period, any contingencies associated with the conversion terms, and the existence and amount of a beneficial conversion feature.

+ References + Details